[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
[3]
|
中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版) [J]. 中华肝脏病杂志, 2017, 25(12): 886-895.
|
[4]
|
Couri, T. and Pillai, A. (2019) Goals and Targets for Personalized Therapy for HCC. Hepatology International, 2, 1-13.
https://doi.org/10.1007/s12072-018-9919-1
|
[5]
|
Wang, L.Y. and Zheng, S.S. (2018) Advances in Predicting the Prognosis of Hepatocellular Carcinoma Recipients after Liver Transplantation. Journal of Zheijang University SCIENCE B, 19, 497-504.
https://doi.org/10.1631/jzus.B1700156
|
[6]
|
Meirelles Junior, R.F., Salvalaggio, P., Rezende, M.B., et al. (2015) Liver Transplantation: History, Outcomes and Perspectives. Einstein (Sao Paulo), 13, 149-152. https://doi.org/10.1590/S1679-45082015RW3164
|
[7]
|
Agopian, V.G., Harlander-Locke, M., Zarrinpar, A., et al. (2015) A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Trans-plantation: Analysis of 865 Consecutive Liver Transplant Recipients. Journal of the American College of Surgeons, 220, 416-427.
https://doi.org/10.1016/j.jamcollsurg.2014.12.025
|
[8]
|
Chapman, W.C., Garcia-Aroz, S., Vachharajani, N., et al. (2017) Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging without Up-Front Stage Re-strictions. Journal of the American College of Surgeons, 224, 610-621. https://doi.org/10.1016/j.jamcollsurg.2016.12.020
|
[9]
|
Rudnick, S.R. and Russo, M.W. (2018) Liver Transplan-tation beyond or Downstaging within the Milan Criteria for Hepatocellular Carcinoma. Expert Review of Gastroenter-ology & Hepatology, 12, 265-275.
https://doi.org/10.1080/17474124.2018.1417035
|
[10]
|
Akoad, M.E. and Pomfret, E.A. (2015) Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. Clinical Liver Disease, 19, 381-399. https://doi.org/10.1016/j.cld.2015.01.007
|
[11]
|
Hirokawa, F., Hayashi, M., Miyamoto, Y., et al. (2015) Predictors of Poor Prognosis by Recurrence Patterns after Curative Hepatectomy for Hepatocellular Carcinoma in Child-Pugh Classification A. Hepatogastroenterology, 62, 164-168.
|
[12]
|
Au, K.P. and Chok, K.S.H. (2018) Multidisciplinary Ap-proach for Post-Liver Transplant Recurrence of Hepatocellular Carcinoma: A Proposed Management Algorithm. World Journal of Gastroenterology, 24, 5081-5094.
https://doi.org/10.3748/wjg.v24.i45.5081
|
[13]
|
Regalia, E., Fassati, L.R., Valente, U., et al. (1998) Pattern and Management of Recurrent Hepatocellular Carcinoma after Liver Transplantation. Journal of Hepato-Biliary-Pancreatic Surgery, 5, 29-34.
https://doi.org/10.1007/PL00009947
|
[14]
|
Roayaie, S., Schwartz, J.D., Sung, M.W., et al. (2004) Recurrence of Hepatocellular Carcinoma after Liver Transplant: Patterns and Prognosis. Liver Transplantation, 10, 534-540. https://doi.org/10.1002/lt.20128
|
[15]
|
Zimmerman, M.A., Ghobrial, R.M., Tong, M.J., et al. (2008) Recurrence of Hepatocellular Carcinoma Following Liver Transplantation: A Review of Preoperative and Postoperative Prognostic Indicators. Archives of Surgery, 143, 182-188; Discussion 188. https://doi.org/10.1001/archsurg.2007.39
|
[16]
|
De’angelis, N., Landi, F., Carra, M.C., et al. (2015) Managements of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Systematic Review. World Journal of Gastro-enterology, 21, 11185-11198.
https://doi.org/10.3748/wjg.v21.i39.11185
|
[17]
|
关智芬, 陈伟强. 肝移植术后复发性肝细胞癌的多学科治疗[J]. 岭南现代临床外科, 2018, 18(5): 589-592.
|
[18]
|
Mazzaferro, V., Regalia, E., Doci, R., et al. (1996) Liver Trans-plantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. The New England Journal of Medicine, 334, 693-699.
https://doi.org/10.1056/NEJM199603143341104
|
[19]
|
Yao, F.Y., Ferrell, L., Bass, N.M., et al. (2001) Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival. Hepatology, 33, 1394-1403.
https://doi.org/10.1053/jhep.2001.24563
|
[20]
|
Zheng, S.S., Xu, X., Wu, J., et al. (2008) Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences. Transplantation, 85, 1726-1732. https://doi.org/10.1097/TP.0b013e31816b67e4
|
[21]
|
Marsh, J.W., Dvorchik, I., Bonham, C.A., et al. (2000) Is the Pathologic TNM Staging System for Patients with Hepatoma Predictive of Outcome. Cancer, 88, 538-543.
https://doi.org/10.1002/(SICI)1097-0142(20000201)88:3<538::AID-CNCR7>3.0.CO;2-H
|
[22]
|
Jonas, S., Mittler, J., Pascher, A., et al. (2007) Living Donor Liver Transplantation of the Right Lobe for Hepatocellular Carcinoma in Cirrhosis in a European Center. Liver Transplantation, 13, 896-903. https://doi.org/10.1002/lt.21189
|
[23]
|
Sugawara, Y., Tamura, S. and Makuuchi, M. (2007) Living Donor Liver Transplantation for Hepatocellular Carcinoma: Tokyo University Series. Digestive Diseases, 25, 310-312. https://doi.org/10.1159/000106910
|
[24]
|
Lee, S.G., Hwang, S., Moon, D.B., et al. (2008) Expanded Indication Criteria of Living Donor Liver Transplantation for Hepatocellular Carcinoma at One Large-Volume Center. Liver Transplantation, 14, 935-945.
https://doi.org/10.1002/lt.21445
|
[25]
|
Mazzaferro, V., Llovet, J.M., Miceli, R., et al. (2009) Predicting Survival after Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Retrospective, Exploratory Analysis. The Lancet Oncology, 10, 35-43. https://doi.org/10.1016/S1470-2045(08)70284-5
|
[26]
|
Fan, J., Yang, G.S., Fu, Z.R., et al. (2009) Liver Transplantation Outcomes in 1,078 Hepatocellular Carcinoma Patients: A Multi-Center Experience in Shanghai, China. Journal of Cancer Research and Clinical Oncology, 135, 1403-1412.
https://doi.org/10.1007/s00432-009-0584-6
|
[27]
|
Li, J., Yan, L.N., Yang, J., et al. (2009) Indicators of Prognosis after Liver Transplantation in Chinese Hepatocellular Carcinoma Patients. World Journal of Gastroenterology, 15, 4170-4176. https://doi.org/10.3748/wjg.15.4170
|
[28]
|
Kim, J.H., Sinn, D.H., Gwak, G.Y., et al. (2016) Factors Determining Long-Term Outcomes of Hepatocellular Carcinoma within the Milan Criteria: Liver Transplantation versus Locoregional Therapy: A Retrospective Cohort Study. Medicine (Baltimore), 95, e4735. https://doi.org/10.1097/MD.0000000000004735
|
[29]
|
Yao, F.Y., Mehta, N., Flemming, J., et al. (2015) Down-staging of Hepatocellular Cancer before Liver Transplant: Long-Term Outcome Compared to Tumors within Milan Criteria. Hepatology, 61, 1968-1977.
https://doi.org/10.1002/hep.27752
|
[30]
|
Xu, X., Lu, D., Ling, Q., et al. (2016) Liver Transplantation for Hepato-cellular Carcinoma beyond the Milan Criteria. Gut, 65, 1035-1041. https://doi.org/10.1136/gutjnl-2014-308513
|
[31]
|
Levi Sandri, G.B., Rayar, M., Qi, X., et al. (2018) Liver Trans-plant for Patients outside Milan Criteria. Translational Gastroenterology and Hepatology, 3, 81. https://doi.org/10.21037/tgh.2018.10.03
|
[32]
|
Shimamura, T., Akamatsu, N., et al. (2018) Expanded Living-Donor Liver Transplantation Criteria for Patients with Hepatocellular Carcinoma Based on the Japanese Nationwide Survey: The 5-5-500 Rule—A Retrospective Study. Transplant International.
|
[33]
|
Chen, J., Xu, X., Wu, J., et al. (2014) The Stratifying Value of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma. PLoS ONE, 9, e93128. https://doi.org/10.1371/journal.pone.0093128
|
[34]
|
Qu, Z., Ling, Q., Gwiasda, J., et al. (2018) Hangzhou Criteria Are More Accurate than Milan Criteria in Predicting Long-Term Survival after Liver Transplantation for HCC in Germany. Langenbeck’s Archives of Surgery, 403, 643-654. https://doi.org/10.1007/s00423-018-1696-8
|
[35]
|
Audet, M., Panaro, F., Piardi, T., et al. (2009) Are the Hangzhou Criteria Adaptable to Hepatocellular Carcinoma Patients for Liver Transplantation in Western Countries? Liver Trans-plantation, 15, 822-823.
https://doi.org/10.1002/lt.21765
|
[36]
|
Fan, S.T. (2008) Selection of HCC Patients for Liver Transplantation: The Milan Criteria, Hangzhou Criteria and beyond. Hepatobiliary & Pancreatic Diseases International, 7, 233-234.
|
[37]
|
Duvoux, C., Roudot-Thoraval, F., Decaens, T., et al. (2012) Liver Transplantation for Hepatocellular Carcinoma: A Model Including Alpha-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology, 143, 986-994.
https://doi.org/10.1053/j.gastro.2012.05.052
|
[38]
|
Toso, C., Asthana, S., Bigam, D.L., et al. (2009) Reassessing Selection Criteria Prior to Liver Transplantation for Hepatocellular Carcinoma Utilizing the Scientific Registry of Transplant Recipients Database. Hepatology, 49, 832-838.
https://doi.org/10.1002/hep.22693
|
[39]
|
Toso, C., Meeberg, G., Hernandez-Alejandro, R., et al. (2015) Total Tumor Volume and Alpha-Fetoprotein for Selection of Transplant Candidates with Hepatocellular Carcinoma: A Prospective Validation. Hepatology, 62, 158-165.
https://doi.org/10.1002/hep.27787
|
[40]
|
Han, K., Tzimas, G.N., Barkun, J.S., et al. (2007) Preoperative Alpha-Fetoprotein Slope Is Predictive of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Canadian Journal of Gastroenterology, 21, 39-45.
https://doi.org/10.1155/2007/206383
|
[41]
|
Dumitra, T.C., Dumitra, S., Metrakos, P.P., et al. (2013) Pretransplantation Alpha-Fetoprotein Slope and Milan Criteria: Strong Predictors of Hepatocellular Carcinoma Recurrence after Transplantation. Transplantation, 95, 228-233.
https://doi.org/10.1097/TP.0b013e31827743d7
|
[42]
|
Citores, M.J., Lucena, J.L., De La Fuente, S., et al. (2019) Serum Biomarkers and Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. World Journal of Hepatology, 11, 50-64. https://doi.org/10.4254/wjh.v11.i1.50
|
[43]
|
Yang, N., Li, Z., Yan, M., et al. (2019) Evaluation of Serum Alpha-Fetoprotein Level in Chronic Hepatitis C Patients. Clinical Laboratory, 65.
|
[44]
|
Schieving, J.H., De Vries, M., Van Vugt, J.M., et al. (2014) Alpha-Fetoprotein, a Fascinating Protein and Biomarker in Neurology. European Journal of Paediatric Neurology, 18, 243-248. https://doi.org/10.1016/j.ejpn.2013.09.003
|
[45]
|
Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022.
https://doi.org/10.1002/hep.24199
|
[46]
|
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 4, 908-943.
|
[47]
|
Benson, A.B., D’angelica, M.I., Abrams, T.A., et al. (2014) Hepatobiliary Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network, 12, 1152-1182. https://doi.org/10.6004/jnccn.2014.0112
|
[48]
|
Chaiteerakij, R., Zhang, X., Addissie, B.D., et al. (2015) Combinations of Biomarkers and Milan Criteria for Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation. Liver Transplantation, 21, 599-606.
https://doi.org/10.1002/lt.24117
|
[49]
|
Pote, N., Cauchy, F., Albuquerque, M., et al. (2015) Performance of PIVKA-II for Early Hepatocellular Carcinoma Diagnosis and Prediction of Microvascular Invasion. Journal of Hepatology, 62, 848-854.
https://doi.org/10.1016/j.jhep.2014.11.005
|
[50]
|
Hong, Y.M., Cho, M., Yoon, K.T., et al. (2017) Risk Factors of Early Recurrence after Curative Hepatectomy in Hepatocellular Carcinoma. Tumor Biology, 39, 1010428317720863. https://doi.org/10.1177/1010428317720863
|
[51]
|
Takada, Y., Ito, T., Ueda, M., et al. (2007) Living Donor Liver Transplantation for Patients with HCC Exceeding the Milan Criteria: A Proposal of Expanded Criteria. Digestive Diseases, 25, 299-302. https://doi.org/10.1159/000106908
|
[52]
|
Yang, K., Lee, T.B., Choi, B.H., et al. (2016) Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings, 48, 3317-3322.
https://doi.org/10.1016/j.transproceed.2016.08.050
|
[53]
|
Kim, S.H., Moon, D.B., Kim, W.J., et al. (2016) Preoperative Prognostic Values of Alpha-Fetoprotein (AFP) and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) in Patients with Hepatocellular Carcinoma for Living Donor Liver Transplantation. Hepatobiliary Surgery and Nutrition, 5, 461-469.
https://doi.org/10.21037/hbsn.2016.11.05
|
[54]
|
De Stefano, F., Chacon, E., Turcios, L., et al. (2018) Novel Biomarkers in Hepatocellular Carcinoma. Digestive and Liver Disease, 50, 1115-1123. https://doi.org/10.1016/j.dld.2018.08.019
|
[55]
|
Kulik, L. and El-Serag, H.B. (2019) Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 156, 477-491.e471. https://doi.org/10.1053/j.gastro.2018.08.065
|
[56]
|
Kinoshita, A., Onoda, H., Imai, N., et al. (2015) C-Reactive Protein as a Prognostic Marker in Patients with Hepatocellular Carcinoma. Hepatogastroenterology, 62, 966-970.
|
[57]
|
Chan, S.L. and Chan, A.W. (2017) Systematic Evaluation of Circulating Inflammatory Markers for Hepatocellular Carcinoma. Liver International, 37, 280-289.
|
[58]
|
An, H.J., Jang, J.W., Bae, S.H., et al. (2012) Serum C-Reactive Protein Is a Useful Biomarker for Predicting Outcomes after Liver Transplantation in Patients with Hepatocellular Carcinoma. Liver Transplantation, 18, 1406-1414.
https://doi.org/10.1002/lt.23512
|
[59]
|
Kornberg, A., Witt, U., Kornberg, J., et al. (2016) Postoperative Peak Serum C-Reactive Protein Is a Predictor of Outcome Following Liver Transplantation for Hepatocellular Carcinoma. Biomarkers, 21, 152-159.
https://doi.org/10.3109/1354750X.2015.1118548
|
[60]
|
Halazun, K.J., Aldoori, A., Malik, H.Z., et al. (2008) Elevated Preoperative Neutrophil to Lymphocyte Ratio Predicts Survival Following Hepatic Resection for Colorectal Liver Metastases. European Journal of Surgical Oncology, 34, 55-60. https://doi.org/10.1016/j.ejso.2007.02.014
|
[61]
|
Halazun, K.J., Hardy, M.A., Rana, A.A., et al. (2009) Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome after Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 250, 141-151.
https://doi.org/10.1097/SLA.0b013e3181a77e59
|
[62]
|
Yoshizumi, T., Ikegami, T., Yoshiya, S., et al. (2013) Impact of Tumor Size, Number of Tumors and Neutrophil-to-Lymphocyte Ratio in Liver Transplantation for Recurrent Hepatocellular Carcinoma. Hepatology Research, 43, 709-716. https://doi.org/10.1111/hepr.12016
|
[63]
|
Najjar, M., Agrawal, S., Emond, J.C., et al. (2018) Pretreatment Neutrophil-Lymphocyte Ratio: Useful Prognostic Biomarker in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 5, 17-28.
https://doi.org/10.2147/JHC.S86792
|
[64]
|
Xu, Z.G., Ye, C.J., Liu, L.X., et al. (2018) The Pretransplant Neutrophil-Lymphocyte Ratio as a New Prognostic Predictor after Liver Transplantation for Hepatocellular Cancer: A Systematic Review and Meta-Analysis. Biomarkers in Medicine, 12, 189-199. https://doi.org/10.2217/bmm-2017-0307
|
[65]
|
Xia, W., Ke, Q., Wang, Y., et al. (2015) Predictive Value of Pre-Transplant Platelet to Lymphocyte Ratio for Hepatocellular Carcinoma Recurrence after Liver Transplantation. World Journal of Surgical Oncology, 13, 60.
https://doi.org/10.1186/s12957-015-0472-2
|
[66]
|
Pinato, D.J., Stebbing, J., Ishizuka, M., et al. (2012) A Novel and Validated Prognostic Index in Hepatocellular Carcinoma: The Inflammation Based Index (IBI). Journal of Hepatology, 57, 1013-1020.
https://doi.org/10.1016/j.jhep.2012.06.022
|
[67]
|
Lai, Q., Melandro, F., Larghi Laureiro, Z., et al. (2018) Platelet-to-Lymphocyte Ratio in the Setting of Liver Transplantation for Hepatocellular Cancer: A Systematic Review and Meta-Analysis. World Journal of Gastroenterology, 24, 1658-1665. https://doi.org/10.3748/wjg.v24.i15.1658
|
[68]
|
Han, S., Lee, S., Yang, J.D., et al. (2018) Risk of Posttransplant Hepatocellular Carcinoma Recurrence Is Greater in Recipients with Higher Platelet Counts in Living Donor Liver Transplantation. Liver Transplantation, 24, 44-55.
https://doi.org/10.1002/lt.24961
|
[69]
|
Xia, W., Ke, Q., Guo, H., et al. (2017) Expansion of the Milan Criteria without Any Sacrifice: Combination of the Hangzhou Criteria with the Pre-Transplant Platelet-to-Lymphocyte Ratio. BMC Cancer, 17, 14.
https://doi.org/10.1186/s12885-016-3028-0
|